Description

Cosentyx (secukinumab) binds and neutralizes interleukin?17A (IL?17A), a pro?inflammatory cytokine involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis. By blocking IL?17A, secukinumab reduces inflammation and modulates immune signaling. Widely used in research to model autoimmune inflammation, IL?17 signaling dynamics, and test novel anti?cytokine therapies. Administered subcutaneously via 150?mg/mL pre?filled syringe or auto?injector. Packaged as individual syringes. Strictly for laboratory research use only.

Cosentyx (Secukinumab) Product Specifications

Cosentyx (Secukinumab) Mechanism of Action & Research Applications

Secukinumab is an IL?17A inhibitor that suppresses inflammation by blocking the cytokine signaling cascade mediated via Th17 cells. In research settings, Cosentyx is used to model:

• Immune-mediated inflammation pathways

• Psoriasiform skin, joint inflammation, and spondyloarthritis models

• IL?17 signaling and cytokine modulation assays

• Proof-of-concept studies for anti-cytokine therapies in vitro and in vivo

Cosentyx (Secukinumab) Side Effects (For Reference Only in Research Models)

Experimental analogs and clinical data suggest possible observations such as:

• Upper respiratory infections, nasopharyngitis

• Diarrhea, oral herpes, rash, or injection-site redness

• Rare inflammatory bowel disease exacerbations

• Anaphylaxis or hypersensitivity in latex-sensitive protocols
  Monitor inflammatory markers and model tolerability parameters accordingly.

Disclaimer

Cosentyx (secukinumab) Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.